-
Something wrong with this record ?
Cost-effectiveness of coronary artery bypass graft and percutaneous coronary intervention compared to medical therapy in patients with coronary artery disease: a systematic review
SS. Gholami, FEF. Azar, A. Rezapour, M. Tajdini,
Language English Country United States
Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, Systematic Review
NLK
ProQuest Central
from 1999-01-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2005-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 1999-01-01 to 1 year ago
- MeSH
- Cost-Benefit Analysis methods MeSH
- Percutaneous Coronary Intervention economics methods MeSH
- Coronary Artery Bypass economics methods MeSH
- Quality-Adjusted Life Years MeSH
- Humans MeSH
- Coronary Artery Disease drug therapy psychology surgery MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
- Systematic Review MeSH
- Geographicals
- England MeSH
- Argentina MeSH
- Brazil MeSH
- Czech Republic MeSH
- Mexico MeSH
- Netherlands MeSH
- Austria MeSH
- United States MeSH
- Switzerland MeSH
- Wales MeSH
Coronary artery disease (CAD) has significant social and economic implications. It is necessary to create tools to identify the most cost-effectiveness treatments, which can assist clinicians in their therapeutic decisions so that the maximum possible benefit is reached with the lowest possible cost. Effectiveness must be measured by final treatment goals in which the most effective interventions are those with the lowest costs. This study is aimed to systematically review and compare the studies conducted on the cost-effectiveness of the three coronary artery disease treatment strategies (medical treatment, percutaneous coronary intervention, and coronary artery bypass graft). In this systematic review, the databases NHS Economic Evaluation Database, Embase, MEDLINE, Science Direct, and Scopus were searched for studies on the cost-effectiveness of coronary artery bypass graft (CABG) and percutaneous coronary intervention (PCI) compared to medical therapy (MT) in patients with coronary artery disease between 1 January 2004 to 30 September 2018. The quality appraisal of the included studies was examined using the Consolidated Health Economics Evaluation Reporting Standards (CHEERS) statement. Out of 186 unique retrievals, 8 studies were included. The results showed that the all studies clearly stated the time horizon of the study and included direct medical costs in their analysis. In addition, in most of the studies, quality-adjusted life years (QALY) were the main outcome used for measuring the effectiveness. The studies reported various ranges of the incremental cost-effectiveness ratio (ICER); accordingly, the highest ratio was observed in the USA ($212,800) for PCI v MT and the lowest ratio was observed in Brazil ($4403) for CABG v MT. Although the results of the studies were different in terms of a number of aspects, such as the viewpoint of the study, the study horizons, and the costs of expenditure items, they reached similar results. Based on the result of the present study, it seems that each three treatment strategies for CAD yielded improvements in QALY.
Health Management and Economics Research Center Iran University of Medical Sciences Tehran Iran
Tehran Heart Center Tehran University of Medical Sciences Tehran Iran
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20015864
- 003
- CZ-PrNML
- 005
- 20201119104844.0
- 007
- ta
- 008
- 201012s2019 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s10741-019-09811-3 $2 doi
- 035 __
- $a (PubMed)31179517
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Gholami, Saeed Sheikh $u Department of Health Economics, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran.
- 245 10
- $a Cost-effectiveness of coronary artery bypass graft and percutaneous coronary intervention compared to medical therapy in patients with coronary artery disease: a systematic review / $c SS. Gholami, FEF. Azar, A. Rezapour, M. Tajdini,
- 520 9_
- $a Coronary artery disease (CAD) has significant social and economic implications. It is necessary to create tools to identify the most cost-effectiveness treatments, which can assist clinicians in their therapeutic decisions so that the maximum possible benefit is reached with the lowest possible cost. Effectiveness must be measured by final treatment goals in which the most effective interventions are those with the lowest costs. This study is aimed to systematically review and compare the studies conducted on the cost-effectiveness of the three coronary artery disease treatment strategies (medical treatment, percutaneous coronary intervention, and coronary artery bypass graft). In this systematic review, the databases NHS Economic Evaluation Database, Embase, MEDLINE, Science Direct, and Scopus were searched for studies on the cost-effectiveness of coronary artery bypass graft (CABG) and percutaneous coronary intervention (PCI) compared to medical therapy (MT) in patients with coronary artery disease between 1 January 2004 to 30 September 2018. The quality appraisal of the included studies was examined using the Consolidated Health Economics Evaluation Reporting Standards (CHEERS) statement. Out of 186 unique retrievals, 8 studies were included. The results showed that the all studies clearly stated the time horizon of the study and included direct medical costs in their analysis. In addition, in most of the studies, quality-adjusted life years (QALY) were the main outcome used for measuring the effectiveness. The studies reported various ranges of the incremental cost-effectiveness ratio (ICER); accordingly, the highest ratio was observed in the USA ($212,800) for PCI v MT and the lowest ratio was observed in Brazil ($4403) for CABG v MT. Although the results of the studies were different in terms of a number of aspects, such as the viewpoint of the study, the study horizons, and the costs of expenditure items, they reached similar results. Based on the result of the present study, it seems that each three treatment strategies for CAD yielded improvements in QALY.
- 650 _2
- $a koronární bypass $x ekonomika $x metody $7 D001026
- 650 _2
- $a nemoci koronárních tepen $x farmakoterapie $x psychologie $x chirurgie $7 D003324
- 650 _2
- $a analýza nákladů a výnosů $x metody $7 D003362
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a koronární angioplastika $x ekonomika $x metody $7 D062645
- 650 _2
- $a kvalitativně upravené roky života $7 D019057
- 650 _2
- $a výsledek terapie $7 D016896
- 651 _2
- $a Argentina $x epidemiologie $7 D001118
- 651 _2
- $a Rakousko $x epidemiologie $7 D001317
- 651 _2
- $a Brazílie $x epidemiologie $7 D001938
- 651 _2
- $a Česká republika $x epidemiologie $7 D018153
- 651 _2
- $a Anglie $x epidemiologie $7 D004739
- 651 _2
- $a Mexiko $x epidemiologie $7 D008800
- 651 _2
- $a Nizozemsko $x epidemiologie $7 D009426
- 651 _2
- $a Švýcarsko $x epidemiologie $7 D013557
- 651 _2
- $a Spojené státy americké $x epidemiologie $7 D014481
- 651 _2
- $a Wales $x epidemiologie $7 D014852
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a systematický přehled $7 D000078182
- 700 1_
- $a Azar, Farbod Ebadi Fard $u Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran. dr_febadi@yahoo.com.
- 700 1_
- $a Rezapour, Aziz $u Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran.
- 700 1_
- $a Tajdini, Masih $u Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
- 773 0_
- $w MED00007617 $t Heart failure reviews $x 1573-7322 $g Roč. 24, č. 6 (2019), s. 967-975
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31179517 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201012 $b ABA008
- 991 __
- $a 20201119104841 $b ABA008
- 999 __
- $a ok $b bmc $g 1584291 $s 1106032
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 24 $c 6 $d 967-975 $e - $i 1573-7322 $m Heart failure reviews $n Heart Fail Rev $x MED00007617
- LZP __
- $a Pubmed-20201012